,i #aaeth ,,congress #b;d ,session ,h4 ,r4 #eiad ,,in ,,the ,,house ,,of ,,representatives ,may #bb1 #bjah,mr4 ,meadows introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to require a study and report on policy and regulatory changes that may have contributed to the opioid epidemic4 #a4 ,,gao study and report on policy changes that may have contributed to the opioid epidemic ,not later than #b years after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall complete a study and submit a report to ,congress on health care policy changes that may have contributed to the increase in opioid overdoses and deaths during the #aj years preceding the date of enactment of this ,act4 ,such study shall include-- 7#a7 a review of health care-related legislative1 administrative1 and judicial decisions by officers and employees of the ,federal ,government that have affected access to pain management strategies with an emphasis on pharmaceuticals2 7#b7 an analysis of what is known about the costs and benefits1 whether financial or nonfinancial1 of reversing or revising such decisions individually or in combination1 including whether the reversals or revisions would be expected to achieve a reduction in abuse of1 addiction to1 overdose on1 and death from opioids2 7#c7 an analysis of the differences among ,state-based prescription drug monitoring programs1 including an analysis of what is known about the effects of such differences on monitoring for abuse of1 addiction to1 overdose on1 and death from opioids2 7#d7 an analysis of what is known about positive and negative impacts that prescribing limitations1 both ,state and ,federal1 have on patient medical outcomes1 including for chronic pain patients2 and 7#e7 an analysis of what is known about the costs and benefits to payers of using abuse-deterrent formulations of opioid pain medications1 compared to opioid pain medications without abuse-deterrent features4